NEUROENDOCRINE TUMOURS Updated December 2015 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary)

Size: px
Start display at page:

Download "NEUROENDOCRINE TUMOURS Updated December 2015 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary)"

Transcription

1 NEUROENDOCRINE TUMOURS Updated December 2015 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Cynthia Card (Staff Medical Oncologist, University of Calgary) DISCLAIMER: The following are study notes compiled by the above PGY-5 medical oncology residents and reviewed by a staff medical oncologist. They reflect what we feel is relevant knowledge for graduating medical oncology residents preparing for their final examination. The information has not been surveyed or ratified by the Royal College. Neuroendocrine (NE) cells are located in almost every body tissue. NE cells are part of the Diffuse Endocrine System (DES) that can release hormones in response to a variety of stimuli to regulate normal physiological functions. Neuroendocrine Tumors (NETs) arise from NE cells. NETs are most commonly found in the gastrointestinal tract and pancreas. The term carcinoid syndrome refers to the collection of symptoms that are precipitated by secretory NETs. The term carcinoid was introduced by Oberndorfer in 1907 to describe NETs. It was previously felt that these tumors were not truly cancerous, so the term carcinoid implied a benign tumor. Unfortunately, this has led to some misconception about NETs. NETs can display variable biological behaviors, ranging from benign to very aggressive tumors. A) PUBLIC HEALTH EPIDEMIOLOGY - Incidence: 4.7 per 100, Mortality: Not well-described. RISK FACTORS - Environmental/Chemical/Infections: Whether there is an association between bronchial NETs and smoking is unclear. Causality has not been proven. - Genetic: most are sporadic but bronchial NETs can rarely occur in the setting of multiple endocrine neoplasia type 1 (MEN1). Type 2 gastric NETs can occur in the context of MEN1. Most pancreatic NETs are sporadic but can be associated with MEN1, von Hippel Lindau, neurofibromatosis type 1, and tuberous sclerosis. PREVENTION & SCREENING - Prevention: nothing described. - Screening: nothing described. B) PRESENTATION & DIAGNOSIS SYMPTOMS & SIGNS - Common Symptoms/Signs/Presentations: Organized by site of origin of NET.! Stomach: Type % of all gastric NETs. Arise from enterochromaffin-like cells (ECL cells). Associated with chronic atrophic gastritis and pernicious anemia. Patients may be asymptomatic or may present with abdominal pain, anemia, or reflux symptoms. Type 2 5% of all gastric NETs. Occur in association with gastrinomas (Zollinger-Ellison syndrome), often in the setting of MEN1. Patients may present with hypergastrinemia symptoms of peptic ulcer disease. Type 3 20% of all gastric NETs and are usually the most aggressive. Local or hepatic mets is usually found on presentation. Fasting serum gastrin levels are usually normal in these patients.

2 !! Lung Patients with bronchial NETs can present with a carcinoid syndrome (flushes, sweats, diarrhea) that is severe and prolonged. This usually occurs in patients that have liver mets as well. Flushes may be associated with disorientation, anxiety and tremor. The majority of tumours arise in the proximal airways and symptoms occur due to an obstructing mass causing bleeding or respiratory symptoms. Beware of inducing a carcinoid crisis in attempts to biopsy. The patient may require pretreatment with a somatostatin analogue prior to biopsy if there is a risk of inducing a carcinoid crisis. Bronchial NETs may be associated with a hilar or a perihilar mass on CXR. The minority of cases can present as a peripheral solitary pulmonary nodule. Some patients may present with a Cushing s syndrome. Pancreas 50-75% of pancreatic NETs are nonfunctioning while the rest are functioning and may produce insulin, gastrin, glucagon, somatostatin or VIP. Gastrinomas and insulinomas are the two most common pancreatic NETs. See table 1 below for features of selected syndromes.

3 Table 1 Features and Investigations of Selected Syndromes! Small bowel many patients are asymptomatic at presentation and the small bowel NET is found incidentally. Among symptomatic patients, abdominal pain is the most common presenting symptom. Some patients may present with a bowel obstruction, intussusception, or bowel ischemia. Liver mets is very common. Can present with a carcinoid syndrome (see table 1).! Appendix Most patients are asymptomatic. When the tumour occurs at the base of the appendix, they may cause bowel obstruction leading to appendicitis. o NETs arising from the colon, rectum and GU tracts are usually nonsecretory and NOT associated with a carcinoid syndrome, even when they metastasize.! Colon usually asymptomatic unless the tumours are large. If there are symptoms, they are similar to colorectal adenocarcinoma symptoms of changes in bowel habits, obstruction or bleeding. Patients may also present with abdominal pain, anorexia or weight loss. The majority of colonic NETs are located in the right colon, particularly in the cecum.! Rectum vast majority are asymptomatic and found incidentally on rectal exam or endoscopy.! GU hindgut NETs arising from the renal or testicular systems have been described in case reports. These lesions typically present as an abdominal or testicular mass. Some can occasionally present with a carcinoid syndrome.! Ovary Primary NETs are usually unilateral and often arise within a cystic teratoma or dermoid tumour. In contrast, metastatic ovarian NETs are usually bilateral, originate in the small intestine and can present with peritoneal carcinomatosis. The ovary drains directly into the systemic circulation so ovarian carcinoids can produce carcinoid syndrome without hepatic mets. Some ovarian carcinoids can produce a hormone that decreases gut motility and causes severe constipation. INVESTIGATIONS Laboratory: - Serum chromogranin A: useful marker for both functioning and nonfunctioning NETs - 24hr urine 5-HIAA: useful for the diagnosis and follow-up of NETs, especially mid-gut NETs. Measure 24hr urine 5-HIAA even if not presenting with carcinoid syndrome symptoms. If elevated, patients need to be on surveillance for carcinoid heart disease. - Other: specific to the secreted hormone ex. Insulin for insulinoma, gastrin for gastrinoma, etc. - Parietal cell antibodies for stomach NETs - MEN1 is excluded with normal serum calcium, PTH and possibly pituitary hormones - Calcitonin, somatostatin - Serum acid phosphatase and HCG levels may be elevated in patients with hindgut NETs. Pathology: - Well vs poorly differentiated appearance - Expression of NE markers such as synaptophysin and chromogranin on immunohistochemistry (IHC) - Ki67 (+/- mitotic rate) to determine if G1, G2 or G3 - IHC staining for specific hormones as dictated by clinical presentation

4 Diagnostic Imaging: - Anatomic imaging with CT or MRI. - Conventional PET is not useful for well-differentiated NETs but can be useful for poorly differentiated NETs. - Octreotide scan (using 111Indium-penetreotide scintigraphy): useful for both functioning and nonfunctioning NETs. Octreotide scan avidity can predict response to octreotide therapy. - MIBG (metaiodobenzylguanidine) scintigraphy: some NETs will take up MIBG and not octreotide. - Consider Echocardiogram if concerned about carcinoid heart syndrome or elevated 24hr urine 5- HIAA. Diagnostic Procedures: may need to pursue endoscopy to obtain a tissue diagnosis. Beware of inducing a carcinoid crisis in attempts to biopsy suspected bronchial NETs. If there is a risk of inducing a carcinoid crisis, pretreat the patient with a somatostatin analogue. PATHOLOGY & MOLECULAR BIOLOGY - Common Histology: WHO Classification 2010 is used for digestive tract NETs; the 2004 is used for bronchial NETs. o Digestive tract NETs:! Neuroendocrine tumor grade 1 (G1) (carcinoid)! Neuroendocrine tumor grade 2 (G2)! Neuroendocrine carcinoma (large cell or small cell type)! Mixed adenoneuroendocrine carcinoma (MANEC) o! Hyperplastic and preneoplastic lesions Bronchial NETs:! Typical carcinoid (1-2%): < 2 mitotic figures per 10 HPF; no necrosis! Atypical carcinoid ( %): 2-10 mf/10hpf! Large cell neuroendocrine tumour (3%)! Small cell neuroendocrine tumour (20%) -> aka poorly differentiated - Common Metastatic Sites: liver, omentum, ovaries - Relevant Molecular Biology: none known. STAGING - TNM: There is a separate TNM staging system for NETs of the appendix, pancreas, stomach, small bowel/ampulla of Vater, and colorectal primary sites 3. - Other: European Neuroendocrine Tumour Society/World Health Organization Nomenclature and classification for NETs 2 o Well-differentiated:! Low grade (G1) mitotic count <2 per 10 high power field (HPF), Ki-67 <3%! Intermediate grade (G2) mitotic count 2-20 per HPF, Ki % o Poorly differentiated:! High grade (G3) mitotic count >20 per 10 HPF, Ki-67 > 20% C) TREATMENT Treatment of NETs has be divided into: i) GastroEnteroPancreatic NETs (GEP-NETs) - The term GastroEnteroPancreatic (GEP- NETs) is now used to encompass the broad range of NETs arising from the GI tract or pancreas. GEP-NETs are subdivided into: - Pancreatic NETs - Midgut GEP-NETs (ie. Ileo-jejunal and appendix) - Other GEP-NETs (ie. Stomach and duodenal) ii) Colorectal NETs arising from the colon or rectum. iii) Bronchial NETs arising from the bronchopulmonary system.

5 GEP-NETs: PANCREATIC NETs - Bottom Line General Approach: - Role of surgery/local therapies: - For pancreatic NETs (pnets), surgery can be curative. Cytoreductive surgery can be considered in the presence of liver mets if the majority of the tumour can be safely removed. Consider cytoreductive surgery in the presence of liver mets to delay disease progression. - Patients with extensive liver mets with functional pnet can also be considered for liver-directed therapies such as radiofrequency ablation, embolization, chemoembolization and radiolabeled microspheres. - Surgery can also be considered in cases of advanced symptomatology due to hormone excess state. Biotherapy - Somatostatin analogues are the primary treatment in patients with symptomatic functioning pnets, particularly those of low proliferation (G1) (see PROMID study summarized in table below; also see CLARINET study listed in references). Somatostatin analogues may also delay tumour progression. Chemotherapy and Targeted Agents - Well-differentiated pnets: o First-line therapy: Streptozocin-based chemotherapy is recommended for metastatic pnets. Streptozocin is used in combination with 5-FU or Doxorubicin. Capecitabine and temozolomide is also effective in metastatic pnets. o Historically, interferon has shown some effectiveness in pnet patients, especially in symptom-control, dating back to the 1980 s. However, the toxicity profile and inconvenient dosing of interferon have rendered it no longer recommended for treatment of pnet patients. o Second-line therapy: Patients may be treated with targeted agents sunitinib or everolimus. Sunitinib and everolimus are generally considered after the failure of systemic chemotherapy. However, the choice and sequence of systemic therapy is determined by disease-related factors, patient preferences, potential therapy-related adverse effects and assessed by the medical oncologist. o Third-line therapy: Patients with progressive and/or symptomatic NETs whose tumours are MIBG and/or octreotide-avid, and the avidity is durable, may be considered for peptide receptor radionuclide therapy (PRRT) 1. This therapy is still considered largely experimental in most of the world. o In Alberta, Dr Sandy McEwan and colleagues at the Cross Cancer Centre in Edmonton have been using PRRT since the late 1990 s in NET patients. Two PRRT s are currently available: I-131 MIBG and Lutetium-177 Octreotide. - Poorly-differentiated pnets: o Patients with poorly-differentiated pnets should be treated with cisplatin and etoposide chemotherapy. o The majority of patients present with advanced disease but some can present with localized disease amenable to surgical resection. Patients should be referred to medical oncology after surgery for consideration of adjuvant chemotherapy. Prognosis: Well-differentiated pnets have an overall survival rate of 80% at 5 years. Median survival for advanced well differentiated PNETs is 60 months. For poorly differentiated pnets, median survival statistics are similar to what is quoted for other small cell cancers, with ~1 month without treatment, but 8-10 months with chemotherapy.

6 - Important Phase III Clinical Trials: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Rinke A et al. J Clin Oncol. 2009;27(28):4656. Regimen Octreotide LAR 30mg intramuscularly q monthly vs placebo Mechanism of Somatostatin analog. Binds to somatostatin receptors and inhibits Action of serotonin secretion Experimental Drug Primary Endpoint TTP Inclusion/Exclusion Criteria Unresectable midgut NET with no prior systemic treatment Well-differentiated histology KPS > 60% No curative therapeutic options Size (N) 85 patients randomized Results Survival: HR for OS was 0.81 DFS/PFS/TTP: median TTP in octreotide group vs placebo was 14.3 mos vs 6 mos, respectively Response Rate: X vs. X Quality of Life: Toxicity Hematologic toxicity Nausea/diarrhea Fatigue fever Conclusion Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs. Because of the low number of observed deaths, survival analysis was not confirmatory. Other Comments Small numbers

7 Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. Raymond E et al. N Engl J Med. 2011;364(6):501. Regimen Sunitinib 37.5mg po od vs. placebo Mechanism of Tyrosine kinase receptor inhibitor. Inhibits multiple tyrosine kinase Action of receptors including platelet-derived growth factors (PDGFRα and Experimental Drug PDGFRβ), vascular endothelial growth factors (VEGFR1, VEGFR2, and VEGFR3), FMS-like tyrosine kinase-3 (FLT3), colony-stimulating factor type 1 (CSF-1R), and glial cell-line-derived neurotrophic factor receptor (RET). Primary Endpoint PFS Inclusion/Exclusion Criteria Well-differentiated pancreatic NET Unresectable ECOG 0 or 1 Size (N) 171 patients Results Survival: median OS for sunitinib vs placebo 30.5 mos vs mos, respectively. DFS/PFS/TTP: median PFS for sunitinib vs placebo 11.4 mos vs. 5.5 mos, respectively. Response Rate: Objective RR in sunitinib group vs placebo 9.3% vs. 0%, respectively. Quality of Life: no overall difference was noted between the two arms. Toxicity Diarrhea, nausea, vomiting, fatigue, asthenia Conclusion Continuous daily administration of sunitinib at a dose of 37.5 mg improved progression-free survival, overall survival, and the objective response rate as compared with placebo among patients with advanced pancreatic neuroendocrine tumors. Other Comments (e.g. any criticisms about the study)

8 Everolimus for Advanced Pancreatic Neuroendocrine Tumors (RADIANT-3) Yao JC et al. N Engl J Med. 2011;364(6):514 Regimen Everolimus 10mg po od vs placebo Mechanism of Mechanistic target of rapamycin (mtor) inhibitor. Reduces protein Action of synthesis and cell proliferation by binding to the FK binding protein- Experimental Drug 12 (FKBP-12), an intracellular protein, to form a complex that inhibits activation of mtor (mechanistic target of rapamycin) serinethreonine kinase activity. Also reduces angiogenesis by inhibiting vascular endothelial growth factor (VEGF). Primary Endpoint PFS Inclusion/Exclusion Criteria Low-grade or intermediate-grade unresectable pancreatic NET ECOG 0 or 1 Prior antineoplastic therapy was NOT an exclusion criterion Size (N) 410 patients Results Survival: hazard ratio for disease progression or death from any cause with everolimus, 0.35 DFS/PFS/TTP: median PFS for everolimus vs placebo 11.0 vs. 4.6 months, respectively. Toxicity Grade 1 or 2: Stomatitis, rash, diarrhea, fatigue, infections (primarily upper respiratory), pneumonitis, interstitial lung disease Grade 3 or 4: Anemia, hyperglycemia, stomatitis, thrombocytopenia, diarrhea, hypophosphatemia, and neutropenia. Conclusion Everolimus, as compared with placebo, significantly prolonged progression-free survival among patients with progressive advanced pancreatic neuroendocrine tumors and was associated with a low rate of severe adverse events. Other Comments (e.g. any criticisms about the study) - Other Important Published Data: 1. PRRT: Kwekkeboom DJ, de Herder WW, Kam BL, et al: Treatment with the radiolabeled somatostatin analog [ 177 Lu-DOTA 0,Tyr 3 ]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: CLARINET study: Caplin et al. Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors. N Engl J Med 2014; 371: GEP-NETs: MIDGUT NETs - Midgut NETs are those arising from the midgut (lower jejunum, ileum and appendix). - Bottom Line General Approach: - Role of surgery/local therapies: - For midgut NETs confined to the bowel, surgery can be curative. Cytoreductive surgery can be considered in the presence of liver mets if the majority of the tumour can be safely removed. Consider removal of the primary tumour even in the presence of mets to prevent intestinal obstruction or ischemic complications. If unresectable, selective chemoembolization with doxorubicin chemotherapy is a feasible option. Patients with liver mets can also be considered for radiofrequency ablation. - There is no indication for adjuvant or neoadjuvant chemotherapy for jejuno-ileal NETs. - For appendiceal NETs, appendectomy can be curative if the tumour is located at the tip of the appendix, is well-differentiated and is <2cm. A right hemicolectomy is indicated if: tumour is 1-2cm with positive or unclear margins or with deep meso-appendiceal involvement, vascular or perineural invasion is present, location of the tumour at the base of the appendix, histology is

9 consistent with goblet cell carcinoid or mixed endocrine-exocrine tumour. Tumours >2cm should be treated with right hemicolectomy. - Patients with goblet-cell carcinomas of the appendix should be referred to a medical oncologist after surgical resection for consideration of adjuvant chemotherapy with FOLFOX (similar to adjuvant treatment of colonic adenocarcinomas). Biotherapy - Somatostatin analogues are indicated for patients with functional midgut NETs, especially in patients with carcinoid syndrome; it is effective in 50% of patients (see PROMID study summarized in table below; also see CLARINET study listed in references). Somatostatin analogues may also delay tumour progression. - Chemotherapy and Targeted Agents - Well-differentiated midgut NETs: o Chemotherapy is generally not used in well-differentiated midgut NETs as the response rates are < 10%. Agents that can be considered are: single-agent doxorubicin or 5-FU, dacarbazine and the combination of dacarbazine, 5-FU and epiadriamycin. o The role of targeted agents is currently being studied. o Patients with progressive and/or symptomatic NETs whose tumours are MIBG and/or octreotide-avid, and the avidity is durable, may be considered for peptide receptor radionuclide therapy (PRRT) 1. This therapy is still considered largely experimental in most of the world. o In Alberta, Dr Sandy McEwan and colleagues at the Cross Cancer Centre in Edmonton have been using PRRT since the late 1990 s in NET patients. Two PRRT s are currently available: I-131 MIBG and Lutetium-177 Octreotide. - Poorly-differentiated midgut NETs: - For poorly-differentiated NETs, cisplatin plus etoposide chemotherapy may be effective. - Carcinoid heart disease - Carcinoid heart disease should be followed with annual echocardiogram +/- MRI. Referral to a cardiac surgeon is encouraged in patients with tricuspid and/or pulmonary valvular heart disease. The role of octreotide in suppressing 5-HIAA levels to protect against heart damage is controversial. - Prognosis: - The prognosis of patients with metastatic distal small bowel NETs with liver mets is 10yr OS of 15-25%. - Most patients with appendiceal NETs present with localized disease and have 5yr OS of 85-95%. - Important Phase III Clinical Trials: - See PROMID study summarized in table above. - Other Important Published Data: 1. Caplin ME et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors (CLARINET). N Engl J Med Jul;371(3): Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Öberg KE, Janson ET, Eriksson BK. Treatment with cisplatin and etoposide in patients with neuroendocrine tumours. Cancer 2001;92(5):

10 OTHER GEP-NETs Stomach NETs - Bottom Line General Approach: - Localized/Adjuvant/Locally Advanced Disease: - For type 1 and type 2: o <1 cm: surveillance with OGD yearly o Multiple or >1 cm: endoscopic resection, then yearly OGD o Locally advanced or recurrent: resection or antrectomy o For type 3 and poorly differentiated tumours, partial or total gastrectomy with lymph node dissection. There is no standard for adjuvant or systemic treatment and depends on the clinical centre. o Recurrent disease despite local resection: gastrectomy and LN dissection o Somatostatin analogues can control disease for type 1 and type 2. - Metastatic Disease: o Somatostatin analogues can control the secretory symptoms of the tumour o Well-differentiated stomach NETs: streptozocin/5-fu chemotherapy is recommended. o Poorly-differentiated stomach NETs: platinum and etoposide. - Prognosis: Type 1: recurrence-free survival of 24 months and 100% survival 6. Types 2 and 3 are more likely to metastasize and so the prognosis is poorer, exact prognosis not well described. - Important Phase III Clinical Trials: none. - Other Important Published Data: none. Duodenal NETs - Bottom Line General Approach: Surgical removal of the tumour or pancreaticoduodenal resection/whipple s procedure can be curative for localized disease. - There is no standard for adjuvant or systemic treatment and depends on the clinical centre. - See Metastatic Disease for stomach NETs as systemic treatment is similar for duodenal NETs. - For gastrin-producing tumours, proton pump inhibitors should be used to control acid-related symptoms. - Prognosis: The 5-year survival of duodenal NETs is felt to be similar to all GI foregut NETs which is 80 95% for local disease, 65 75% with regional involvement only, and 20 40% for the 5 10% of patients with liver or distant disease. - Important Phase III Clinical Trials: none. - Other Important Published Data: none. COLORECTAL NETs These are NETs involving the colon and/or rectum. - Bottom Line General Approach: - Localized/Adjuvant/Locally Advanced Disease: - Colonic NETs > 2cm in size, tumours with muscularis invasion, and G3 tumours should be treated according to colon adenocarcinoma guidelines (ie. Surgical resection with hemicolectomy). - Rectal NETs > 2cm in size, T3 or T4 stage, with G3 grading, or lymph node-positive rectal tumours should be treated according to rectal adenocarcinoma guidelines (ie. Surgical resection with total mesorectal excision or abdominoperineal resection depending on distance from anal verge). - Adjuvant chemotherapy after surgery can be considered for G3/poorly-differentiated tumours with incomplete resection, although the evidence is lacking. - Metastatic Disease: - Carcinoid syndrome is uncommon in colorectal NETs and should be treated with somatostatin analogues if occurring. Evidence is lacking for the use of somatostatin analogues as anti-tumour agents. - Palliative surgery may be considered for debulking.

11 - Patients with extensive liver mets can also be considered for liver-directed therapies such as radiofrequency ablation, embolization, chemoembolization and radiolabeled microspheres. - Well-differentiated colorectal NETs: o Systemic chemotherapy is rarely indicated for G1 or G2 colorectal NETs. In the setting of progressive disease, streptozocin-based chemotherapy may be considered. There may also be a role for temozolomide-based chemotherapy. o Anti-angiogenesis and mtor inhibitors are not used for colorectal NETs outside the setting of a clinical trial. o Patients with progressive and/or symptomatic NETs whose tumours are MIBG and/or octreotide-avid, and the avidity is durable, may be considered for peptide receptor radionuclide therapy (PRRT) 1. This therapy is still considered largely experimental in most of the world. The evidence for PRRT in the colorectal NET population is minimal, but results in NETs arising from other sites are encouraging. o In Alberta, Dr Sandy McEwan and colleagues at the Cross Cancer Centre in Edmonton have been using PRRT since the late 1990 s in NET patients. Two PRRT s are currently available: I-131 MIBG and Lutetium-177 Octreotide. - Poorly-differentiated colorectal NETs: platinum and etoposide. - Prognosis: Typically years. Exact prognosis not well described. - Important Phase III Clinical Trials: none. - Other Important Published Data: none. BRONCHIAL NETs - Bottom Line General Approach: - Localized/Adjuvant/Locally Advanced Disease: - Complete surgical resection with parenchymal sparing is recommended. Wide resection margins are not required. For elderly patients or patients who are poor surgical candidates, a bronchoscopic resection can be considered. Systematic lymph node dissection is recommended in lymph node positive disease. - There is currently no role for adjuvant/neoadjuvant systemic treatment. - Metastatic Disease: - Carcinoid syndrome can be treated with somatostatin analogues if occurring. - Well-differentiated colorectal NETs: o Chemotherapy with capecitabine and temozolomide in many expert centres despite the lack of level I evidence for this. o o Anti-angiogenesis and mtor inhibitors use in bronchial NETs are under investigation. Patients with progressive and/or symptomatic NETs whose tumours are MIBG and/or octreotide-avid, and the avidity is durable, may be considered for peptide receptor radionuclide therapy (PRRT) 1. This therapy is still considered largely experimental in most of the world. o In Alberta, Dr Sandy McEwan and colleagues at the Cross Cancer Centre in Edmonton have been using PRRT since the late 1990 s in NET patients. Two PRRT s are currently available: I-131 MIBG and Lutetium-177 Octreotide. - Poorly-differentiated colorectal NETs: platinum and etoposide. - Prognosis: Typical Carcinoid: 94% 5yr OS. Atypical Carcinoid: 72% 5yr OS. D) OTHER REFERENCES (not previously sited above) - (e.g. Alberta Health Services/Cancer Care Ontario/BC Cancer Agency Clinical Practice Guidelines, ASCO Guidelines, Canadian Cancer Statistics 2015, UpToDate) - 1. Yao JC et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18): Uptodate - 3. American Joint Committee on Cancer 7 th edition - 4. Alberta Cancer Guidelines

12 - 5. BC Cancer Agency Clinical Practice Guidelines - 6. European Neuroendocrine Tumour guidelines 2012

NET und NEC. Endoscopic and oncologic therapy

NET und NEC. Endoscopic and oncologic therapy NET und NEC Endoscopic and oncologic therapy Classification well-differentiated NET - G1 and G2 - carcinoid poorly-differentiated NEC - G3 - like SCLC well differentiated NET G3 -> elevated proliferation

More information

GI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust

GI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust GI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust Introduction Carcinoid was old term, introduced in 1906 by German pathologist Cancinoma like More recent

More information

MEDICAL MANAGEMENT OF METASTATIC GEP-NET

MEDICAL MANAGEMENT OF METASTATIC GEP-NET MEDICAL MANAGEMENT OF METASTATIC GEP-NET Jeremy Kortmansky, MD Associate Professor of Clinical Medicine Yale Cancer Center DISCLOSURES: NONE Introduction Gastrointestinal and pancreatic neuroendocrine

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL NEUROENDOCRINE GASTRO-ENTERO-PANCREATIC TUMOURS GI Site Group Neuroendocrine gastro-entero-pancreatic tumours Authors: Dr.

More information

Color Codes Pathology and Genetics Medicine and Clinical Pathology Surgery Imaging

Color Codes Pathology and Genetics Medicine and Clinical Pathology Surgery Imaging Saturday, November 5, 2005 8:30-10:30 a. m. Poorly Differentiated Endocrine Carcinomas Chairman: E. Van Cutsem, Leuven, Belgium 9:00-9:30 a. m. Working Group Sessions Pathology and Genetics Group leaders:

More information

TRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS

TRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS TRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS Jaume Capdevila Unitat de Tumors GI i Endocrins Hospital Universitari Vall d Hebron Barcelona Experts, acollidors i solidaris OUTLINE BACKGROUND

More information

Carcinoid Tumors: The Beginning and End. Surgical Oncology Update 2011 Chris Baliski MD, FRCS BC Cancer Agency, CSI October 21, 2011

Carcinoid Tumors: The Beginning and End. Surgical Oncology Update 2011 Chris Baliski MD, FRCS BC Cancer Agency, CSI October 21, 2011 Carcinoid Tumors: The Beginning and End Surgical Oncology Update 2011 Chris Baliski MD, FRCS BC Cancer Agency, CSI October 21, 2011 1 st described by Oberndofer(1907) Karzinoide = cancer like Arise from

More information

Review of Gastrointestinal Carcinoid Tumors: Latest Therapies

Review of Gastrointestinal Carcinoid Tumors: Latest Therapies Review of Gastrointestinal Carcinoid Tumors: Latest Therapies Arvind Dasari, MD, MS Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, TX, USA Neuroendocrine

More information

Neuroendocrine Tumors: Just the Basics. George Fisher, MD PhD

Neuroendocrine Tumors: Just the Basics. George Fisher, MD PhD Neuroendocrine Tumors: Just the Basics George Fisher, MD PhD Topics that we will not discuss Some types of lung cancer: Small cell neuroendocrine lung cancer Large cell neuroendocrine lung cancer Some

More information

Surgical Therapy of GEP-NET: An Overview

Surgical Therapy of GEP-NET: An Overview Surgical Therapy of GEP-NET: An Overview Pierce K.H Chow MBBS, MMed, FRCSE, FAMS, PhD Professor, Duke-NUS Graduate School of Medicine Senior Consultant Surgeon, Singapore General Hospital Visiting Senior

More information

Cutting Edge Treatment of Neuroendocrine Tumors

Cutting Edge Treatment of Neuroendocrine Tumors Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE

More information

Cutting Edge Treatment of Neuroendocrine Tumors

Cutting Edge Treatment of Neuroendocrine Tumors Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE

More information

EXOCRINE: 93% Acinar Cells Duct Cells. ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others

EXOCRINE: 93% Acinar Cells Duct Cells. ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others EXOCRINE: 93% Acinar Cells Duct Cells Digestive Enzymes Trypsin: Digests Proteins Lipases: Digests Fats Amylase: Digest Carbohydrates ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others Hormones Glucagon

More information

Gastrinoma: Medical Management. Haley Gallup

Gastrinoma: Medical Management. Haley Gallup Gastrinoma: Medical Management Haley Gallup Also known as When to put your knife down Gastrinoma Definition and History Diagnosis Historic Management Sporadic vs MEN-1 Defining surgical candidates Nonsurgical

More information

Oberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide)

Oberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide) GEP-NET Adel K. El-Naggar, M.D., Ph.D. The University of Texas MD Anderson Cancer Center, Houston, Texas Oberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide) 1 Histogenesis 16 different

More information

NEUROENDOCRINE CARCINOID TUMORS PANCREATIC NEUROENDOCRINE TUMORS

NEUROENDOCRINE CARCINOID TUMORS PANCREATIC NEUROENDOCRINE TUMORS University of Miami Jackson Memorial Hospital Role of the Surgeon in the Approach to Neuroendocrine tumors Dido Franceschi, MD Professor of Surgery University of Miami Karzinoide Siegfried Oberndorfer,

More information

Neuroendocrine Tumors

Neuroendocrine Tumors Neuroendocrine Tumors Neuroendocrine tumors arise from cells that release a hormone in response to a signal from the nervous system. Neuro refers to the nervous system. Endocrine refers to the hormones.

More information

ENDOLUMINAL APPROACH FOR THE MANAGEMENT OF GASTROINTESTINAL CARCINOID

ENDOLUMINAL APPROACH FOR THE MANAGEMENT OF GASTROINTESTINAL CARCINOID ENDOLUMINAL APPROACH FOR THE MANAGEMENT OF GASTROINTESTINAL CARCINOID Manoop S. Bhutani, MD, FASGE, FACG, FACP, AGAF, Doctor Honoris Causa Professor of Medicine Eminent Scientist of the Year 2008, World

More information

NET εντέρου Τι νεότερο/ Νέες μελέτες. Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ

NET εντέρου Τι νεότερο/ Νέες μελέτες. Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ NET εντέρου Τι νεότερο/ Νέες μελέτες Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ NET: A Diverse Group of Malignancies 1-3 Wide spectrum of malignancies arising in neuroendocrine cells throughout the body

More information

Strategies in the Management of Neuroendocrine Tumors. Dr. Jean Maroun Dr. Elena Tsvetkova

Strategies in the Management of Neuroendocrine Tumors. Dr. Jean Maroun Dr. Elena Tsvetkova Strategies in the Management of Neuroendocrine Tumors Dr. Jean Maroun Dr. Elena Tsvetkova 1 A ZORSE 2 Neuroendocrine Tumour Classification Neuroendocrine Tumours Carcinoid Tumours Pancreatic Neuroendocrine

More information

NICaN Pancreatic Neuroendocrine Tumour SACT protocols. 1.0 Dr M Eatock Final version issued

NICaN Pancreatic Neuroendocrine Tumour SACT protocols. 1.0 Dr M Eatock Final version issued Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Neuro-endocrine Tumours Dr Martin Eatock, Consultant Medical Oncologist & on behalf of the GI Oncologists Group,

More information

Community Case. Saeed Awan R5

Community Case. Saeed Awan R5 Community Case Saeed Awan R5 18 year old presents to ER with history of pain right lower quadrant for three days. Nauseated, denies vomiting and bowel movements normal and no urinary complaint. Admitted

More information

SCOPE TODAYS SESSION. Case 1: Case 2. Basic Theory Stuff: Heavy Stuff. Basic Questions. Basic Questions

SCOPE TODAYS SESSION. Case 1: Case 2. Basic Theory Stuff: Heavy Stuff. Basic Questions. Basic Questions MONDAY TEACHING SCOPE TODAYS SESSION Case 1: Basic Questions Case 2 Basic Questions Basic Theory Stuff: AJCC TNM + Stage Group for Carcinoid of the Appendix Management of Carcinoid of the Appendix (NCCN)

More information

Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors

Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO)

More information

Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid

Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid The Medical Oncology Perspective Nevena Damjanov, MD Associate professor Abramson Cancer Center of the University

More information

Surgical Management of Neuroendocrine Tumors of the Gut. Richard Hodin MD Professor of Surgery Massachusetts General Hospital Harvard Medical School

Surgical Management of Neuroendocrine Tumors of the Gut. Richard Hodin MD Professor of Surgery Massachusetts General Hospital Harvard Medical School Surgical Management of Neuroendocrine Tumors of the Gut Richard Hodin MD Professor of Surgery Massachusetts General Hospital Harvard Medical School Sites of GI Carcinoid Tumors Small intestine 44% Rectum

More information

An Overview of NETS. Richard R.P. Warner M.D

An Overview of NETS. Richard R.P. Warner M.D An Overview of NETS Richard R.P. Warner M.D Diagnosis and Treatment Approaches Carcinoid (and other NETs) not as benign as originally described 13-50% of all carcinoids have distant metastases when first

More information

Treatment algorithm Neuroendocrine tumours. Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece

Treatment algorithm Neuroendocrine tumours. Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece Treatment algorithm Neuroendocrine tumours Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece Outline Presenting a meaningful algorithm Means used to develop algorithm

More information

Rare GI Malignancies

Rare GI Malignancies Rare GI Malignancies Jordan Karlitz, MD Associate Professor of Medicine, Division of Gastroenterology Director, Hereditary GI Cancer and Genetics Program Tulane University School of Medicine Outline Gastrointestinal

More information

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer

More information

2015: Year in Review Results of Recent Trials

2015: Year in Review Results of Recent Trials 2015: Year in Review Results of Recent Trials Pamela L. Kunz, MD Assistant Professor of Medicine / GI Oncology Director, Stanford NET Program Stanford University School of Medicine Disclosures Research

More information

Toward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives

Toward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives Toward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives Moderator: Ashley Grossman, MD, FRCP Professor of Neuroendocrinology William Harvey Research Institute Barts

More information

PNET 3/7/2015. GI and Pancreatic NETs. The Postgraduate Course in Breast and Endocrine Surgery. Decision Tree. GI and Pancreatic NETs.

PNET 3/7/2015. GI and Pancreatic NETs. The Postgraduate Course in Breast and Endocrine Surgery. Decision Tree. GI and Pancreatic NETs. GI and Pancreatic NETs The Postgraduate Course in Breast and Endocrine Surgery Disclosures Ipsen NET Advisory Board Marines Memorial Club and Hotel San Francisco, CA Eric K Nakakura San Francisco, CA March

More information

Evaluation and Management of Neuroendocrine Tumors

Evaluation and Management of Neuroendocrine Tumors Evaluation and Management of Neuroendocrine Tumors Jennifer Chan, MD, MPH Clinical Director, Program in Neuroendocrine and Carcinoid Tumors Dana-Farber/Brigham and Women's Cancer Center October 14, 2017

More information

Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology

Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology OUTLINE Molecular Rationale for the use of SSAs in

More information

OPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS

OPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS OPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS Dr Mairéad McNamara Senior lecturer, University of Manchester & Honorary Consultant in Medical Oncology, The Christie NHS Foundation Trust

More information

NeuroEndocrine Tumors Diagnostic and therapeutic challenges: introduction

NeuroEndocrine Tumors Diagnostic and therapeutic challenges: introduction NeuroEndocrine Tumors Diagnostic and therapeutic challenges: introduction Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be Diagnostic & therapeutic

More information

Management of an Appendiceal Mass - Approach to acute presentation of appendiceal neoplasms

Management of an Appendiceal Mass - Approach to acute presentation of appendiceal neoplasms Management of an Appendiceal Mass - Approach to acute presentation of appendiceal neoplasms Dr. Claudia LY WONG, Department of Surgery, Kwong Wah Hospital Joint Hospital Surgical Grand Round Presentation,

More information

Management of Neuroendocrine Tumors

Management of Neuroendocrine Tumors Management of Neuroendocrine Tumors Professor Barbro Eriksson Department of Endocrine Oncology ENETS Centre of Excellence Uppsala University Hospital Diagnostic Challenges in NET Heterogeneous group of

More information

A) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS

A) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary), April 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Centre, BC Cancer

More information

Pancreatic Neuroendocrine Tumours

Pancreatic Neuroendocrine Tumours UCLH Cancer Collaborative Pancreas Update Meeting 12 th July 2017 Pancreatic Neuroendocrine Tumours Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior

More information

Index. Surg Oncol Clin N Am 15 (2006) Note: Page numbers of article titles are in boldface type.

Index. Surg Oncol Clin N Am 15 (2006) Note: Page numbers of article titles are in boldface type. Surg Oncol Clin N Am 15 (2006) 681 685 Index Note: Page numbers of article titles are in boldface type. A Ablative therapy, for liver metastases in patients with neuroendocrine tumors, 517 with radioiodine

More information

Diagnosing and monitoring NET

Diagnosing and monitoring NET Diagnosing and monitoring NET Inaccurate or delayed diagnosis of neuroendocrine tumors (NET) is common, because many NET are small and asymptomatic. 1 When symptoms are present, they are usually nonspecific

More information

Management of Pancreatic Islet Cell Tumors

Management of Pancreatic Islet Cell Tumors Management of Pancreatic Islet Cell Tumors Ravi Dhanisetty, MD November 5, 2009 Morbidity and Mortality Conference Case Presentation 42 yr female with chronic abdominal pain. PMHx: Uterine fibroids Medications:

More information

EXOCRINE: 93% Acinar Cells Duct Cells. ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others

EXOCRINE: 93% Acinar Cells Duct Cells. ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others EXOCRINE: 93% Acinar Cells Duct Cells Digestive Enzymes Trypsin: Digests Proteins Lipases: Digests Fats Amylase: Digest Carbohydrates ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others Hormones Glucagon

More information

Unexpected Findings at Endoscopy

Unexpected Findings at Endoscopy The Endoscopic Incidentaloma: What to Tell Your Patient t with Unexpected Endoscopic Findings: Gastric Intestinal Metaplasia, Silent Ileitis, Carcinoid David Greenwald, MD Montefiore Medical Center Albert

More information

pan-canadian Oncology Drug Review Final Clinical Guidance Report Sunitinib malate (Sutent) for pancreatic neuroendocrine tumours May 3, 2012

pan-canadian Oncology Drug Review Final Clinical Guidance Report Sunitinib malate (Sutent) for pancreatic neuroendocrine tumours May 3, 2012 pan-canadian Oncology Drug Review Final Clinical Guidance Report Sunitinib malate (Sutent) for pancreatic neuroendocrine tumours May 3, 2012 DISCLAIMER Not a Substitute for Professional Advice This report

More information

Pancreatic neuroendocrine cancer with liver metastases and multiple peritoneal metastases: report of one case

Pancreatic neuroendocrine cancer with liver metastases and multiple peritoneal metastases: report of one case Case Report Pancreatic neuroendocrine cancer with liver metastases and multiple peritoneal metastases: report of one case Yang Wang, Dongbing Zhao Department of Abdominal Surgery, Cancer Institute & Hospital,

More information

Updates in Pancreatic Neuroendocrine Carcinoma Highlights from the 2010 ASCO Annual Meeting. Chicago, IL, USA. June 4-8, 2010

Updates in Pancreatic Neuroendocrine Carcinoma Highlights from the 2010 ASCO Annual Meeting. Chicago, IL, USA. June 4-8, 2010 HIGHLIGHT ARTICLE Updates in Pancreatic Neuroendocrine Carcinoma Highlights from the 2010 ASCO Annual Meeting. Chicago, IL, USA. June 4-8, 2010 Susan Alsamarai 1, Steven K Libutti 2, Muhammad Wasif Saif

More information

Principles of diagnosis, work-up and therapy The Gastroenterologist s role

Principles of diagnosis, work-up and therapy The Gastroenterologist s role Principles of diagnosis, work-up and therapy The Gastroenterologist s role Dr. Christos G. Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University

More information

Type 2 gastric neuroendocrine tumor: report of one case

Type 2 gastric neuroendocrine tumor: report of one case Case Report Type 2 gastric neuroendocrine tumor: report of one case Yuanliang Li, Xin Su, Huangying Tan Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing 100029, China Correspondence

More information

Pancreatic NeuroEndocrine Tumors. Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium

Pancreatic NeuroEndocrine Tumors. Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium Pancreatic NeuroEndocrine Tumors Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium Epidemiology Overall incidence 1.8 to 2.6 SEER, Europe Peak in 5 th and 6 th decade Incidence

More information

Clinical Study Small Bowel Tumors: Clinical Presentation, Prognosis, and Outcomein33PatientsinaTertiaryCareCenter

Clinical Study Small Bowel Tumors: Clinical Presentation, Prognosis, and Outcomein33PatientsinaTertiaryCareCenter Hindawi Publishing Corporation Journal of Oncology Volume 2008, Article ID 212067, 5 pages doi:10.1155/2008/212067 Clinical Study Small Bowel Tumors: Clinical Presentation, Prognosis, and Outcomein33PatientsinaTertiaryCareCenter

More information

Imaging of Neuroendocrine Metastases

Imaging of Neuroendocrine Metastases Imaging of Neuroendocrine Metastases Aoife Kilcoyne, Shaunagh McDermott, Colin McCarthy,Manuel Patino, Dushyant Sahani, Michael Blake Abdominal Imaging Division Massachusetts General Hospital Disclosure

More information

Update on Surgical Management of NETs

Update on Surgical Management of NETs Update on Surgical Management of Neuroendocrine Tumors James R. Howe, M.D. Director, Surgical Oncology and Endocrine Surgery University of Iowa College of Medicine Distribution of NETs 2000-2004 27% ---

More information

Selection of Appropriate Treatment

Selection of Appropriate Treatment Expert Review in Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Selection of Appropriate Treatment Reference Slide Deck Neuroendocrine Tumors (NETs): A Diverse Group of Malignancies

More information

Cross-sectional Imaging of Neuroendocrine Tumors of the Gastrointestinal Tract

Cross-sectional Imaging of Neuroendocrine Tumors of the Gastrointestinal Tract Cross-sectional Imaging of Neuroendocrine Tumors of the Gastrointestinal Tract Eric J. May 1, Shannon P. Sheedy 1, Joel G. Fletcher 1, Mark J. Truty 2, Thomas C. Smyrk 3, Jeff L. Fidler 1 1. Radiology,

More information

Peptide Receptor Radionuclide Therapy using 177 Lu octreotate

Peptide Receptor Radionuclide Therapy using 177 Lu octreotate Peptide Receptor Radionuclide Therapy using 177 Lu octreotate BLR Kam, Erasmus Medical Centre, Rotterdam DJ Kwekkeboom, Erasmus Medical Centre, Rotterdam Legal aspects As 177 Lu-[DOTA 0 -Tyr 3 ]octreotate

More information

Pathology testing and Neuroendocrine tumours (NETs)

Pathology testing and Neuroendocrine tumours (NETs) Pathology testing and Neuroendocrine tumours (NETs) NETs are probably far more common than we think. Most grow so slowly and produce such widely varied and non-specific symptoms, or no symptoms at all,

More information

Lu 177-Dotatate (Lutathera) Therapy Information

Lu 177-Dotatate (Lutathera) Therapy Information Lu 177-Dotatate (Lutathera) Therapy Information Information for Lu 177-dotatate therapy also known as Lutathera, for the treatment of metastatic midgut neuroendocrine tumor and other metastatic neuroendocrine

More information

Hepatic metastases of neuroendocrine tumors: treatment options and outcomes of local patients treated with radioembolization

Hepatic metastases of neuroendocrine tumors: treatment options and outcomes of local patients treated with radioembolization Hepatic metastases of neuroendocrine tumors: treatment options and outcomes of local patients treated with radioembolization JP King PGY2 May 22, 2015 Neuroendocrine Tumor (NET) WHO Classification Location

More information

AN ARGUMENT FOR SURGERY FOR GASTRINOMA. Lauren Wilson R1 General Surgery

AN ARGUMENT FOR SURGERY FOR GASTRINOMA. Lauren Wilson R1 General Surgery AN ARGUMENT FOR SURGERY FOR GASTRINOMA Lauren Wilson R1 General Surgery WHAT IS A GASTRINOMA? Gastrin secreting cells derived from multipotential stem cells of endodermal origin or enteroendocrine cells

More information

Case Report. Ameya D. Puranik, MD, FEBNM; Harshad R. Kulkarni, MD; Aviral Singh, MD; Richard P. Baum, MD, PhD ABSTRACT

Case Report. Ameya D. Puranik, MD, FEBNM; Harshad R. Kulkarni, MD; Aviral Singh, MD; Richard P. Baum, MD, PhD ABSTRACT Case Report 8-YEAR SURVIVAL WITH A METASTATIC THYMIC NEUROENDOCRINE TUMOR: EMPHASIS ON REDEFINING TREATMENT OBJECTIVES USING PERSONALIZED PEPTIDE RECEPTOR RADIONUCLIDE THERAPY WITH 177 Lu- AND 90 Y-LABELED

More information

Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors

Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic

More information

Neuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC

Neuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC Neuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC Case Study 43 yr old female with a history of a left mastectomy

More information

Disclosure of Relevant Financial Relationships

Disclosure of Relevant Financial Relationships Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS

More information

11/21/13 CEA: 1.7 WNL

11/21/13 CEA: 1.7 WNL Case Scenario 1 A 70 year-old white male presented to his primary care physician with a recent history of rectal bleeding. He was referred for imaging and a colonoscopy and was found to have adenocarcinoma.

More information

WHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer

WHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer WHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer Institute Overview Diagnosis: Gallium scan Biomarkers

More information

Gastric and Colon Cancer. Dr. Andres Wiernik 2017

Gastric and Colon Cancer. Dr. Andres Wiernik 2017 Gastric and Colon Cancer Dr. Andres Wiernik 2017 GASTRIC CANCER Gastric Cancer Classification Epidemiology General principles of Management 25% GE Junction Gastric Cancer 75% Gastric Cancer Epidemiology

More information

Objectives. Terminology 03/11/2013. Pitfalls in the diagnosis of Gastroenteropancreatic Neuroendocrine Tumors. Pathology Update 2013

Objectives. Terminology 03/11/2013. Pitfalls in the diagnosis of Gastroenteropancreatic Neuroendocrine Tumors. Pathology Update 2013 Pitfalls in the diagnosis of Gastroenteropancreatic Neuroendocrine Tumors Pathology Update 2013 Ozgur Mete, MD Consultant in Endocrine Pathology, Department of Pathology, University Health Network Assistant

More information

Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14

Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14 Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14 Contents 14. Neuroendocrine Tumours 161 14.1. Diagnostic algorithm

More information

NET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες

NET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες NETMASTERCLASS 2017: an interactive workshop NET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες Νικόλαος Τσουκαλάς MD, MSc, PhD Ογκολόγος - Παθολόγος, MSc Βιοπληροφορική Επιμελητής Α, Ογκολογικό Τμήμα Νοσηλευτικό

More information

Color Codes Pathology and Genetics Medicine and Clinical Pathology Surgery Imaging

Color Codes Pathology and Genetics Medicine and Clinical Pathology Surgery Imaging Friday, November 4, 2005 11:00-12:20 a. m. Pancreatic Tumors, Session 3 Chairman: D. O Toole, Clichy, France 11:20-11:50 a. m. Working Group Session Pathology and Genetics Group leaders: J. Y. Scoazec,

More information

Hot of the press. Γρηγόριος Καλτσάς MD FRCP Καθηγητής Παθολογίας Ενδοκρινολογίας ΕΚΠΑ

Hot of the press. Γρηγόριος Καλτσάς MD FRCP Καθηγητής Παθολογίας Ενδοκρινολογίας ΕΚΠΑ Hot of the press Γρηγόριος Καλτσάς MD FRCP Καθηγητής Παθολογίας Ενδοκρινολογίας ΕΚΠΑ Outline Diagnostic developments Histopathology Molecular Therapeutic developments Results on PRRT Telotristat in carcinoid

More information

Background. Capdevila J, et al. Ann Oncol. 2018;29(Suppl 8): Abstract 1307O. 1. Dasari A, et al. JAMA Oncol. 2017;3(10):

Background. Capdevila J, et al. Ann Oncol. 2018;29(Suppl 8): Abstract 1307O. 1. Dasari A, et al. JAMA Oncol. 2017;3(10): Efficacy of Lenvatinib in Patients With Advanced Pancreatic (pannets) and Gastrointestinal (ginets) WHO Grade 1/2 (G1/G2) Neuroendocrine Tumors: Results of the International Phase II TALENT Trial (GETNE

More information

Gastroenteropancreatic Neuroendocrine Tumors

Gastroenteropancreatic Neuroendocrine Tumors Gastroenteropancreatic Neuroendocrine Tumors Mauro Cives, MD 1 and Jonathan R. Strosberg, MD 2 1 Assistant Professor, University of Bari, Department of Biomedical Sciences and Human Oncology, Bari, Italy;

More information

Prognostic factors and treatment of gastroenteropancreatic G3 neuroendocrine carcinomas.

Prognostic factors and treatment of gastroenteropancreatic G3 neuroendocrine carcinomas. Prognostic factors and treatment of gastroenteropancreatic G3 neuroendocrine carcinomas. Halfdan Sorbye Medical Oncologist Professor, MD Dept of Oncology Haukeland Univ Hospital Bergen, Norway Gastroenteropancreatic

More information

Review Article Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature

Review Article Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature Hindawi International Journal of Surgical Oncology Volume 2017, Article ID 6424812, 14 pages https://doi.org/10.1155/2017/6424812 Review Article Management Options for Advanced Low or Intermediate Grade

More information

SURGERY OF NETS. Iakovos N Nomikos MD FACS. Director and Chairman, Department of Surgery METAXA Memorial Cancer Hospital Piraeus Greece

SURGERY OF NETS. Iakovos N Nomikos MD FACS. Director and Chairman, Department of Surgery METAXA Memorial Cancer Hospital Piraeus Greece SURGERY OF NETS Iakovos N Nomikos MD FACS Director and Chairman, Department of Surgery METAXA Memorial Cancer Hospital Piraeus Greece Epidemiology 5-fold increase in occurrence of NETS over past 30 years

More information

Nuevas alternativas en el manejo de TNE avanzados

Nuevas alternativas en el manejo de TNE avanzados Nuevas alternativas en el manejo de TNE avanzados Jaume Capdevila Hospital Universitari Vall d Hebron Barcelona Coordinación científica: Dr. Fernando Rivera Hospital Universitario Marqués de Valdecilla,

More information

sunitinib 12.5mg, 25mg, 37.5mg, 50mg hard capsules (Sutent ) SMC No. (698/11) Pfizer Limited

sunitinib 12.5mg, 25mg, 37.5mg, 50mg hard capsules (Sutent ) SMC No. (698/11) Pfizer Limited sunitinib 12.5mg, 25mg, 37.5mg, 50mg hard capsules (Sutent ) SMC No. (698/11) Pfizer Limited 08 April 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and

More information

Adjuvant Chemotherapy for Rectal Cancer: Are we making progress?

Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones

More information

SMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary)

SMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary) SMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Desiree Hao (Staff Medical Oncologist, University of Calgary) and Dr.

More information

NEUROENDOCRINE TUMORS

NEUROENDOCRINE TUMORS NEUROENDOCRINE TUMORS A PRIMER FOR HEALTHCARE PROFESSIONALS Advocating the Right Team, the Right Treatment, at the Right Time for Neuroendocrine (NET) patients and physicians educating I funding I supporting

More information

Neuroendocrine & Carcinoid Tumors

Neuroendocrine & Carcinoid Tumors Neuroendocrine & Carcinoid Tumors Acknowledgment This slide set was medically reviewed by Dr. Yi-Zarn Wang, DDS, PC, MD, FACS in August 2018. Workshop Overview Introductions What Are Neuroendocrine Tumors

More information

Octreotide LAR in neuroendocrine tumours a summary of the experience

Octreotide LAR in neuroendocrine tumours a summary of the experience Endocrinology in oncology Review article Octreotide LAR in neuroendocrine tumours a summary of the experience Agnieszka Kolasińska-Ćwikła, MD, PhD Department of Chemotherapy, Oncology Clinic, Maria Sklodowska-Curie

More information

Navigators Lead the Way

Navigators Lead the Way RN Navigators Their Role in patients with Cancers of the GI tract Navigators Lead the Way Nurse Navigator Defined Nurse Navigator A clinically trained individual responsible for the identification and

More information

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management. Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician

More information

Development of New Treatment Modalities Oncolytic Viruses and Nanotechnique

Development of New Treatment Modalities Oncolytic Viruses and Nanotechnique Development of New Treatment Modalities Oncolytic Viruses and Nanotechnique By Professor Kjell Öberg, M.D., Ph.D. Dept. of Endocrine Oncology, University Hospital, Uppsala, Sweden Nashville Oct. 2011 Hallmarks

More information

TUMORES NEUROENDOCRINOS. Miguel Navarro. Salamanca

TUMORES NEUROENDOCRINOS. Miguel Navarro. Salamanca TUMORES NEUROENDOCRINOS Miguel Navarro. Salamanca Introduction to Neuroendocrine Tumours (NETs) NETs are relatively RARE At least 40 different entities are described arising in different organs. Different

More information

Case Presentation. Marianne Ellen Pavel. Charité University Medicine Berlin. ESMO Preceptorship on GI Neuroendocrine Tumors

Case Presentation. Marianne Ellen Pavel. Charité University Medicine Berlin. ESMO Preceptorship on GI Neuroendocrine Tumors Case Presentation Marianne Ellen Pavel Charité University Medicine Berlin ESMO Preceptorship on GI Neuroendocrine Tumors Session 3; Singapore November 2, 2012 06.11.2012 Medical History 46-year-old man

More information

FRANKLY SPEAKING ABOUT CANCER: NEUROENDOCRINE & CARCINOID TUMORS (NETS)

FRANKLY SPEAKING ABOUT CANCER: NEUROENDOCRINE & CARCINOID TUMORS (NETS) FRANKLY SPEAKING ABOUT CANCER: NEUROENDOCRINE & CARCINOID TUMORS (NETS) Gilda s Club Quad Cities November 5 th, 2018 Joseph Dillon, MD Neuroendocrine Tumor Clinic University of Iowa Hospitals & Clinics

More information

Pancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts)

Pancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts) Pancreas Quizzes Quiz 1 1. The pancreas produces hormones. Which type of hormone producing organ is the pancreas? a. Endocrine b. Exocrine c. Both A and B d. Neither A or B 2. Endocrine indicates hormones

More information

Endocrine Tumors of the Gastrointestinal System. F. V. Nowak Ohio University March 22, 2005

Endocrine Tumors of the Gastrointestinal System. F. V. Nowak Ohio University March 22, 2005 Endocrine Tumors of the Gastrointestinal System F. V. Nowak Ohio University March 22, 2005 Gastroenteropancreatic Endocrine System Clear cells of endodermal origin found in the pancreas, stomach, small

More information

Prolonged Survival in a Patient with Neuroendocrine Tumor of the Cecum and Diffuse Peritoneal Carcinomatosis

Prolonged Survival in a Patient with Neuroendocrine Tumor of the Cecum and Diffuse Peritoneal Carcinomatosis This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the article

More information

Third Line and Beyond: Management of Refractory Colorectal Cancer

Third Line and Beyond: Management of Refractory Colorectal Cancer Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting

More information

Lutetium-DOTA TATE Treatment of inoperable GEP NETs

Lutetium-DOTA TATE Treatment of inoperable GEP NETs Logo 177 Lutetium-DOTA TATE Treatment of inoperable GEP NETs Dr. Augusto Llamas-Olier. Nuclear medicine department. Dr. Maria Cristina Martínez*, Dr. Alfonso Lozano** and Dr. Augusto Llamas-Olier*. *Nuclear

More information

8. The polyp in the illustration can be described as (circle all that apply) a. Exophytic b. Pedunculated c. Sessile d. Frank

8. The polyp in the illustration can be described as (circle all that apply) a. Exophytic b. Pedunculated c. Sessile d. Frank Quiz 1 Overview 1. Beginning with the cecum, which is the correct sequence of colon subsites? a. Cecum, ascending, splenic flexure, transverse, hepatic flexure, descending, sigmoid. b. Cecum, ascending,

More information

A) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS

A) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS GIST (Gastrointestinal stromal tumor) Updated MARCH 2017 by Dr. Doreen Ezeife, PGY-5 Resident, University of Calgary Reviewed by Dr. Jan-Willem Henning (Staff Medical Oncologist, University of Calgary)

More information